---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-042677"
form_type: "8-K"
ticker: "SHPH"
cik: "0001757499"
company_name: "Shuttle Pharmaceuticals Holdings, Inc."
filed_at: "2024-10-28T23:59:59+00:00"
generated_at: "2026-05-30T09:46:25.820090+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Shuttle Pharma completes enrollment agreements for Phase 2 Ropidoxuridine glioblastoma trial

## Summary
- All six trial sites finalized: Georgetown, UNC, UVA, Hackensack, Allegheny Health Network, Miami Cancer Institute.
- Patient screening underway; 40 patients randomized to 1,200 mg/day or 960 mg/day dose groups.
- Optimal dose group will add 14 patients for survival comparison vs historical controls; trial completion in 18-24 months.
- Ropidoxuridine holds FDA Orphan Drug Designation for glioblastoma, offering potential marketing exclusivity.

## SEC filing metadata
- accession: 0001493152-24-042677
- form_type: 8-K
- ticker: SHPH
- cik: 0001757499
- company_name: Shuttle Pharmaceuticals Holdings, Inc.
- filed_at: 2024-10-28T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1757499/000149315224042677/0001493152-24-042677-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1757499/000149315224042677/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-042677
- JSON: https://secwatch.observer/filing/0001493152-24-042677.json
- Plain text: https://secwatch.observer/filing/0001493152-24-042677.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.